Platform Trial in Stage 1 Diabetes: Comparing Golimumab vs Placebo

Summary

The goal of this clinical trial is to learn if golimumab is effective at preventing progression to Stage 2 diabetes in participants with presymptomatic Type 1 Diabetes. The expected duration of this study is approximately 6 years. Participants will: * Take golimumab or placebo injections monthly for the duration of the study or until they are diagnosed with either stage 2 or stage 3 Type 1 Diabetes * Visit a study clinic every 6 months for Oral Glucose Tolerance Tests (OGTTs) and other tests until the end of the study

Timeline

Start

2026-08-08

Primary completion

2032-09-01

Completion

2032-09-01

Drugs

Indications